Nikolaos T Voutsas1, Eleni Papageorgiou2, Alexandra Tantou2, Vassilis A Dimitriou3, Evangelia E Tsironi2,4, Maria Kotoula2. 1. Department of Ophthalmology, University Hospital of Larissa, Mezourlo Area, 41110, Larissa, Greece. ni_vo17@hotmail.com. 2. Department of Ophthalmology, University Hospital of Larissa, Mezourlo Area, 41110, Larissa, Greece. 3. Department of Mathematics, Aristotle University of Thessaloniki, Thessaloniki, Greece. 4. Department of Ophthalmology, Faculty of Medicine, University of Thessaly, Larissa, Greece.
Abstract
INTRODUCTION: Neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DME), and macular oedema due to central retinal vein occlusion (CRVO) are leading causes of vision loss, currently managed with anti-vascular endothelial growth factor injections (anti-VEGF). The aim of this study was to calculate QALYs in patients with nAMD, DME, and CRVO treated with anti-VEGF agents (QALYs+) in a Greek tertiary hospital setting and compare them to theoretical QALYs that the patients would have without treatment (QALYs-). MATERIAL AND METHODS: The study included 143 treatment-naive patients with macular oedema due to nAMD (n = 79), DME (n = 57), and CRVO (n = 7), who received anti-VEGF injections as monotherapy according to the Treat-and-Extend (T&E) protocol. The anti-VEGF agents were ranibizumab and aflibercept in equivalent fractions. QALYs where calculated by the formula QALY = Utility Value × Time, where "Time" refers to the follow-up period of the study. For QALYs-, we assumed that visual acuity remained unchanged during this period. RESULTS: Mean follow-up time was 1.3 ± 1.2 years in the nAMD group, 1 ± 1.3 years in the DME group, and 0.5 ± 1 years in the CRVO group. There was no statistically significant difference between QALYs- and QALYs+ in all three ocular pathologies for the study period (p > 0.05 for each of the three statistical tests performed). DISCUSSION/ CONCLUSION: Possible explanations for the lack of significant difference between QALYs - and QALYs + in nAMD, DME, and CRVO groups, may be the short time horizon used in this analysis, the inclusion of data from the better-seeing eye (BSE) and the specific socio-economic, geographical and health care characteristics of this rural Greek area.
INTRODUCTION: Neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DME), and macular oedema due to central retinal vein occlusion (CRVO) are leading causes of vision loss, currently managed with anti-vascular endothelial growth factor injections (anti-VEGF). The aim of this study was to calculate QALYs in patients with nAMD, DME, and CRVO treated with anti-VEGF agents (QALYs+) in a Greek tertiary hospital setting and compare them to theoretical QALYs that the patients would have without treatment (QALYs-). MATERIAL AND METHODS: The study included 143 treatment-naive patients with macular oedema due to nAMD (n = 79), DME (n = 57), and CRVO (n = 7), who received anti-VEGF injections as monotherapy according to the Treat-and-Extend (T&E) protocol. The anti-VEGF agents were ranibizumab and aflibercept in equivalent fractions. QALYs where calculated by the formula QALY = Utility Value × Time, where "Time" refers to the follow-up period of the study. For QALYs-, we assumed that visual acuity remained unchanged during this period. RESULTS: Mean follow-up time was 1.3 ± 1.2 years in the nAMD group, 1 ± 1.3 years in the DME group, and 0.5 ± 1 years in the CRVO group. There was no statistically significant difference between QALYs- and QALYs+ in all three ocular pathologies for the study period (p > 0.05 for each of the three statistical tests performed). DISCUSSION/ CONCLUSION: Possible explanations for the lack of significant difference between QALYs - and QALYs + in nAMD, DME, and CRVO groups, may be the short time horizon used in this analysis, the inclusion of data from the better-seeing eye (BSE) and the specific socio-economic, geographical and health care characteristics of this rural Greek area.
Authors: Lindsay Claxton; Robert Hodgson; Matthew Taylor; Bill Malcolm; Ruth Pulikottil Jacob Journal: Pharmacoeconomics Date: 2017-02 Impact factor: 4.981
Authors: Suzann Pershing; Eva A Enns; Brian Matesic; Douglas K Owens; Jeremy D Goldhaber-Fiebert Journal: Ann Intern Med Date: 2014-01-07 Impact factor: 25.391
Authors: Usha Chakravarthy; Simon P Harding; Chris A Rogers; Susan Downes; Andrew J Lotery; Helen A Dakin; Lucy Culliford; Lauren J Scott; Rachel L Nash; Jodi Taylor; Alyson Muldrew; Jayashree Sahni; Sarah Wordsworth; James Raftery; Tunde Peto; Barnaby C Reeves Journal: Health Technol Assess Date: 2015-10 Impact factor: 4.014